Cancer Metabolism
Genetic alterations and epigenetic modifications of cancer cells result in cellular metabolic pathways that are different in comparison to normal cells. Due to the inherent genetic instability of cancer cells, tumors are heterogeneous with a myriad microenvironments and multiple altered metabolic pathways, which could provide useful cancer therapeutic targets.
Cancer Metabolism Products Targets
- Ribonucleotide Reductase (2)
- PFKFB3 (3)
- Oxidative Phosphorylation (6)
- NHE (3)
- MTH1 (1)
- Monocarboxylate Transporter (3)
- Monoacylglycerol Lipase (6)
- Lactate Dehydrogenase A (1)
- HMG-CoA Reductase (8)
- Hexokinases (1)
- Glutaminase (1)
- Glucose Transporter (2)
- Fatty Acid Synthase (3)
- Dihydrofolate Reductase (2)
- Carbonic Anhydrase (2)
- ATP Citrate Lyase (3)
Products for Cancer Metabolism - Page 3
- Cat.No. Product Name Information/Activity
-
BCN2569
Simvastatin
HMG-CoA reductase inhibitor,Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM in cell-free assays.
-
BCC7530
SR 12813
SR12813 is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM.
-
BCC5607
GSK 2837808A
GSK2837808A is a potent and selective lactate dehydrogenase A (LDHA) inhibitor with IC50s of 1.9 and 14 nM for LDHA and LDHB, respectively.
-
BCC5610
JJKK 048
JJKK 048 is an ultrapotent and highly selective inhibitor of Monoacylglycerol lipase (MAGL).
-
BCC6324
JW 642
JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.
-
BCC4790
JZL184
JZL 184 is a potent, selective and irreversible monoacylglycerol lipase (MAGL) inhibitor with IC50s of 8 nM and 4 µM for inhibition of MAGL and fatty acid amide hydrolase in mouse brain membranes, respectively.
-
BCC7966
JZL 195
JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively.
-
BCC6312
KML 29
KML29 is a potent and selective MAGL inhibitor with IC50 = 5.9, 15, and 43 nM in human, mouse, and rat brain proteomes, respectively.
-
BCN2315
Pristimerin
Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 of 93 nM.
-
BCC1367
AR-C155858
AR-C155858 is a selective monocarboxylate transporter MCT1 and MCT2 inhibitor with Kis of 2.3 nM and 10 nM, respectively.


